Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
We can help you navigate your options.

Email Us About Clinical Trials
Clinical Trial FAQ

Get answers to frequently asked questions about clinical trials: What are clinical trials? Is a clinical trial the right choice for my child?

FAQ: Participating in Clinical Trials
Top Ranked for Cancer Care

World class cancer care at the #1 children’s cancer center in the Northeast

Learn More

Clinical Trials for Relapsed Cancer

For patients with relapsed, refractory, or recurrent cancer, early phase clinical trials may be a treatment option. Phase I and phase II clinical trials provide access to the newest, most innovative therapies to patients.

The Advancing Childhood Cancer Therapies (ACCT) Clinic is dedicated to offering state-of-the-art therapies, advancing the science of pediatric research, and providing personalized care to you and your family. The clinic includes experts in each type of cancer as well as teams of subspecialists and nurses who are leaders in their respective fields. In August 2016, we joined the Children’s Oncology Group Phase 1 Consortium, one of only 21 such centers in the United States and the only one in New England.

Our currently active phase I and phase II trials for patients with relapsed, recurrent, or refractory cancer are listed below by disease.

If you have questions about which trial might be right for your child or patient, please email us at clinicaltrials@danafarberbostonchildrens.org or call us at 1-855-320-2090. We can help you navigate your options.

Phase I and II Trials for Relapsed and Refractory Cancer

    Bone Tumor and Other Sarcoma Trials
    1. A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma
      Principal Investigator Steven DuBois, MD, MS
      Status: Active/Recruiting
    2. A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK-3 Alterations
      Principal Investigator Steven DuBois, MD, MS
      Status: Active/Recruiting
    3. Phase 2 Proof of Concept Study of Nivolumab and Ipilimumab in Children and Young Adults with Relapsed or Refractory INI1-Negative Cancers
      Principal Investigator Suzanne Forrest, MD
      Status: Active/Recruiting
    Brain Tumor Trials
    1. A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma
      Principal Investigator Steven DuBois, MD, MS
      Status: Active/Recruiting
    2. A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK-3 Alterations
      Principal Investigator Steven DuBois, MD, MS
      Status: Active/Recruiting
    3. Phase 2 Proof of Concept Study of Nivolumab and Ipilimumab in Children and Young Adults with Relapsed or Refractory INI1-Negative Cancers
      Principal Investigator Suzanne Forrest, MD
      Status: Active/Recruiting
    4. FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Altered, Recurrent or Progressive Low-Grade Glioma
      Principal Investigator Susan Chi, MD
      Status: Active/Recruiting
    Kidney, Liver, and Other Solid Tumor Trials
    1. A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma
      Principal Investigator Steven DuBois, MD, MS
      Status: Active/Recruiting
    2. The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates. A Phase II Study
      Principal Investigator Allison O'Neill, MD
      Status: Active/Recruiting
    3. A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK-3 Alterations
      Principal Investigator Steven DuBois, MD, MS
      Status: Active/Recruiting
    4. Phase 2 Proof of Concept Study of Nivolumab and Ipilimumab in Children and Young Adults with Relapsed or Refractory INI1-Negative Cancers
      Principal Investigator Suzanne Forrest, MD
      Status: Active/Recruiting
    5. An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects with Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)
      Principal Investigator Allison O'Neill, MD
      Status: Active/Recruiting
    6. Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study)
      Principal Investigator Elizabeth Lee, MD
      Status: Active/Recruiting
    Leukemia Trial
    1. Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
      Principal Investigator Susanne Baumeister, MD
      Status: Active/Recruiting
    Lymphoma Trials
    1. A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma
      Principal Investigator Steven DuBois, MD, MS
      Status: Active/Recruiting
    2. A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK-3 Alterations
      Principal Investigator Steven DuBois, MD, MS
      Status: Active/Recruiting
    3. Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
      Principal Investigator Angela Feraco, MD, MMSc
      Status: Active/Recruiting